Nov 5, 5:13 PM ET
ANI Pharmaceuticals entered a 364-day senior bridge credit facility of up to $676 million with JPMorgan Chase Bank, N.A. as administrative agent. The facility will be used to finance its recommended public cash offer for Egetis Therapeutics shares, convertible loan and warrants, valued at about SEK 5.6 billion, or approximately $559.9 million, and to refinance ANI's existing term loans and some Egetis debt, which adds significant borrowing and secured obligations for ANI shareholders.
- Facility allows borrowings up to $676 million and matures 364 days after initial funding
- Initial margin of 1.75% for ABR loans and 2.75% for adjusted term SOFR loans
- Offer price is SEK 11.25 per Egetis share; total value about SEK 5.6 billion, or $559.9 million
- Completion requires holders of at least 90% of Egetis shares (fully diluted) to tender and regulatory clearances; undertakings covering 42.2% of shares expire if the offer is not declared unconditional by March 31, 2027
Read the filing on SEC.gov ↗
Nov 5, 6:56 AM ET
ANI Pharmaceuticals reported third quarter 2026 net revenues of $290.8 million, up 27.6%, and GAAP diluted earnings per share of $1.51 versus $1.13 a year earlier. It cut its 2026 Cortrophin Gel revenue guidance to $480 million to $500 million from $520 million to $540 million, citing slower-than-expected conversion of demand into patients, while raising its adjusted EBITDA and adjusted EPS guidance, and it announced a recommended offer to acquire Egetis Therapeutics.
- Q3 2026 Cortrophin Gel net revenues were $138.7 million, up 36.1%, while Brands revenue fell 6.5% to $10.0 million.
- 2026 Cortrophin Gel revenue guidance was revised to $480 million to $500 million, down from $520 million to $540 million; total company revenue guidance was narrowed to $1,085 million to $1,125 million.
- Adjusted non-GAAP EBITDA guidance was raised to $290 million to $300 million, and adjusted non-GAAP diluted EPS guidance was raised to $9.37 to $9.71.
- The Egetis offer is SEK 11.25 per share, valued at approximately $560 million including incentive programs; the acceptance period is expected to run from about November 20, 2026 to December 18, 2026.
Read the filing on SEC.gov ↗
Aug 24, 7:01 AM ET
ANI Pharmaceuticals appointed Henry Gosebruch, former AbbVie strategy chief and former Neumora CEO, as a director effective August 19, 2026. Director Muthusamy Shanmugam resigned from the board on August 23, 2026, but remains an executive as Head of R&D and Chief Operating Officer of New Jersey Operations. The filing describes Gosebruch's role as supporting business development and capital allocation, which is relevant to shareholders as the company pursues its Rare Disease transformation.
- Henry Gosebruch, 53, appointed to the Board with a term expiring at the 2027 annual meeting
- Initial restricted stock award with a grant date fair value of $525,000, vesting in three equal annual installments
- Samy Shanmugam resigned as a director effective immediately on August 23, 2026, and stays in his executive role
Read the filing on SEC.gov ↗
Aug 7, 7:00 AM ET
ANI Pharmaceuticals reported second-quarter 2026 total net revenues of $266.0 million, up 25.9% from a year earlier, and GAAP net income available to common shareholders of $24.7 million, or $1.05 per diluted share, versus $0.36 in the prior-year quarter. The company reaffirmed its full-year total net revenue guidance of $1,080 million to $1,140 million and adjusted non-GAAP EBITDA guidance of $285 million to $300 million, but lowered its Cortrophin Gel net revenue guidance to $520 million to $540 million from $540 million to $575 million, which matters because Cortrophin Gel is the company's largest product.
- Total net revenues were $266.0 million in Q2 2026, up from $211.4 million in Q2 2025.
- Diluted GAAP EPS was $1.05 versus $0.36; adjusted non-GAAP diluted EPS was $2.21 versus $1.80.
- Cortrophin Gel 2026 net revenue guidance was revised to $520 million to $540 million from $540 million to $575 million; total net revenue guidance of $1,080 million to $1,140 million was reaffirmed.
- The board authorized a share repurchase program of up to $100.0 million in common stock through May 2029, effective May 8, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
